ORPHA:715950
Diffuse hemispheric glioma-H3 G34-mutant
How rare: How common this is has not been clearly measured.
Is anyone studying this?
327
327 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
327 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
326 in the last 10 years · low confidence
Is a treatment being tested?
9
trials for this specific condition
9 interventional trials matched this specific condition name; 7 currently recruiting in our sample.
Data as of 26 July 2026
9 interventional trials — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 85.9th percentile).
low confidence · 85.9th percentile (trials denominator)
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Who's working on it?
1,147
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Mastronuzzi A8 papers · 2026
Research Area of Onco-haematology and Pharmaceutical GMP Facility, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
Papers in Europe PMC - 02Rossi S7 papers · 2025
Pathology Unit, Department of Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
Papers in Europe PMC - 03Carai A6 papers · 2026
Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Papers in Europe PMC - 04Vinci M6 papers · 2026
Research Area of Onco-haematology and Pharmaceutical GMP Facility, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy. maria.vinci@opbg.net.
Papers in Europe PMC - 05Aldape K5 papers · 2026
Laboratory of Pathology, National Cancer Institute, Centre for Cancer Research, Bethesda, MD, USA.
Papers in Europe PMC - 06Hu W5 papers · 2025
Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 07Miele E5 papers · 2025
Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. evelina.miele@opbg.net.
Papers in Europe PMC - 08Tauziède-Espariat A5 papers · 2026
Department of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France. a.tauziede-espariat@ghu-paris.fr.
Papers in Europe PMC - 09Varlet P5 papers · 2026
Department of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France.
Papers in Europe PMC - 10Abdullaev Z4 papers · 2026
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07223034·A Study of 177Lu-PSMA-617 in People With Gliomas
- NCT06860594·Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- NCT06896110·Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
- NCT06630260·5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- NCT05843253·Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- NCT06632236·5G-EMERALD: Amivantamab in Malignant Brain Tumours
- NCT06914479·Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Diffuse hemispheric glioma-H3 G34-mutant"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Diffuse hemispheric glioma-H3 G34-mutant"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
0Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low